Roivant Sciences is a biopharmaceutical holding company founded by Vivek Ramaswamy in 2014. It operates a 'Vant' model, creating nimble subsidiary companies (such as Immunovant, Priovant, Genevant, and previously Telavant) focused on developing and commercializing late-stage drug candidates licensed from other pharma companies. Roivant went public on Nasdaq under ticker ROIV in October 2021 via a business combination with Montes Archimedes Acquisition Corp., a SPAC sponsored by Patient Square Capital. The company maintains offices in New York, Boston, and Basel.
Roivant Sciences is publicly traded
This company is no longer available on our private secondary market. Shares can be traded publicly under its listed ticker.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2014
Employees
201–500
Total Funding
$1.3B
2 rounds
Latest Valuation
$7B
November 13, 2018
Total raised $1.3B across 2 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 05-10-2026
Latest Round
Type
Private Equity
Date
November 13, 2018
Amount
$200M
Valuation
$7B
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| November 13, 2018 | Private Equity | $200M | $7B | NovaQuest Capital Management |
| August 9, 2017 | Private Equity | $1.1B | — | SoftBank Vision Fund |
Matt Gline
Chief Executive Officer
Vivek Ramaswamy
Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
BridgeBio Pharma
Hub-and-spoke biopharma operating subsidiary programs across genetic diseases and oncology.
Royalty Pharma
Public biopharma royalty acquirer with overlap in late-stage asset financing.
Ligand Pharmaceuticals
Biotech royalty and platform business that partners on late-stage asset development.
Centessa Pharmaceuticals
Multi-asset biopharma formed by combining 10 subsidiaries; similar Vant-style structure.
Roivant Sciences became publicly traded on Nasdaq under tickers ROIV (shares) and ROIVW (warrants) on October 1, 2021, following the close of its business combination with Montes Archimedes Acquisition Corp. (MAAC), a SPAC sponsored by Patient Square Capital. The transaction was valued at approximately $5 billion and included $411M from the SPAC trust plus a $200M PIPE from investors including Fidelity, Eventide, Suvretta, RTW, Viking, SB Management (SoftBank), Sumitomo Dainippon Pharma, and Palantir.
Roivant Sciences shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker to place an order.
Roivant Sciences had a valuation of approximately $7B at the time of its public offering. Current market capitalization fluctuates with the share price.
Roivant Sciences raised $1.3B across 2 disclosed funding rounds prior to its public listing.
Roivant Sciences was founded by Vivek Ramaswamy in 2014.
Roivant Sciences is headquartered in New York, NY.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.